Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tractor... a VERY long hold. Years imo !
It's called corporate restructuring. Why would Tim care about that 400M shares if in the meantime he has generated millions of $$ via dilution. He got what he wanted. The 400M could be simply symbolic. Also, he will simply issue himself another 400,000,000 shares in the 'new' corporate entity. He will have a social issue though if he persuaded his family and friends into buying a large quantity of shares in TSOI. The SEC simply doesn't have the resources to go after 'ethics' violations in sub-penny stocks on the OTC. Investing in TSOI requires trusting Tim. -- technically TSOI is not on the normal OTC. It's on the pink sheets referred to as "Other OTC". This is barely on the SEC radar screen.
Well, I do FEAR that when Tim is capable of marketing his patents (may take a few years), that he will dissolve this corporate entity making existing shares worthless. Then he will set up a new corporate entity from scratch to 'launch' his new business. Hence, he will make good on his promise to never R/S TSOI. I think there is a high probability that this has been Tim's long-term strategy all along.....so, I never allowed myself to put too much skin in this game. My risk is very low. The grossly high O/S and Float are the major red flags.
But one never really knows. Maybe Tim will surprise everyone in 2025 or 2026 and sell out to the highest bidder and then we all get paid.
If the SEC investigates TSOI and concludes that illegal activity has occurred (whether intentional or not), that could result in the SEC delisting TSOI. We would not want that since that would essentially make all shares of TSOI worthless (not good for incumbent investors !!). It is far wiser to let the winds sail this ship where it may, and hope that something good comes out of it in the end. Delisting by the SEC will wipe out the little equity one currently has.
Rick.. one could argue that Mike may have hired the wrong outfit to conduct the trial. He may have been trying to safe $$. This is exactly what RLFTF did. They hired an outfit that bungled everything up on the end-points.
It would seem to me that RLFTF needs to NOW focus on generating sales and turning a profit off of their existing portfolio of drugs. Rather than pay more salaries and bonuses for more R&D in gene therapy. Where are the $$ going to come from to pay this person. Is RAM's vision a never ending black hole of R&D. It's time to start generating sales and moving toward a profit making enterprise. They are about to do an R/S, and we know where that will take us a year down the road. More dilution to pay for initiatives such as this. JMHO.
Investing in penny stocks is a HIGH RISK decision. Some decisions work out, but many/most are bad decisions in the penny stock space. The SEC has stated that time and time again. The SEC warns the public to stay away from penny stocks unless the risk is acceptable. No one forced anyone to buy QNTA. It's a conscience, decision making process. Accepting the 'high' risk and the consequences of failure is on the investor. To avoid risk, buy CDs. QNTA is not dead just yet. They may still be able to pull a rabbit out of their hat.
How?
It doesn't matter if one is right or wrong. Grieving over a bad decision doesn't solve anything either. Especially when there are lots of other opportunities out there.
They also did not issue a PR immediately preceding the r/s. Which IMO is a total disregard for the SH. Having said that, I realize that many investors here have posted that the lack of a PR is a non-issue. For me though it is an issue. It says something about managements respect for the SH. But it is what it is.
Yes, that is true too. However, a lot of SH don't understand even the structural basics of the r/s because they haven't experienced it yet. Often they are sold a bill of goods by insiders claiming the r/s is used to uplist to the NASDAQ...which often is b.s. IMO ease of dilution to raise $ to pay the bills (salaries) is usually the primary insider goal of an r/s. Ease of price and spread manipulation by market makers is a whole nuther convoluted world -- as you pointed out. I have rarely ever seen a good thing occur from an r/s. It appears that a lot of longs lost a good chunk of equity here after this r/s occurred. I now exit any penny stock position once it becomes clear that an r/s is about to hit the books (which included this one). I view it as risk management.
Mountain, I don't think we will see any PR news until they have something 'real' to say. I'm sure they are paranoid that the SEC is watching what they say to their investors. So I expect long periods of radio silence. We may not hear anything until much later in the year IMO.
Meanwhile, I'm proactively swing trading elsewhere. No sense in grieving over this stock when everything is out of our control. I say..... make money elsewhere, while you wait for this to turn around (if it turns around).
All too many investors don't understand the concept until they themselves get burned. The r/s by itself does not do any damage whatsoever, and that is what the pumpers pump. However, it's the aftermath of dilution that wipes out the SH equity as the pps slides south. I never understood it until I got burned by it myself 20+ years ago. The r/s is the bread and butter of insiders to keep their little penny stock companies alive and breathing so that they can keep drawing their high salaries and bonus checks.
As suspected, it looks lie the Jan R/S didn't hold up well. They almost never do.
I’ve heard that same argument many times. It just doesn’t hold water over the long term.
Yes. That is correct. But I’ve seen plenty of penny stock do it at these o/s levels as well however the lower o/s here does reduce the risk imo!! I read somewhere that MF did do one before in a previous job.
RLFTF just announced they will be doing one. I'll have to lick my wounds on that one when that happens. Dilution always follows. They, like RVVTF, touted a grand covid therapy. That's what these tiny penny stocks do when they need more money to pay their salaries and bonuses. Due to the need to raise funds, the time horizon for making a decent profit with penny stocks is typically very narrow, A few years a ago a wise penny stock investor once posted ---- it's not wise to hold penny stocks that are below a dime with a high o/s for very long, because bad things eventually tend to happen. He is so right!
gov.. High probability that r/s will be next in line. O/S > 320M. JMHO
The ceo was also not ready to launch the trial once the FDA gave the green light....even though he had many months to prepare in advance. Months got lost in him setting up and launching trial after the FDA gave the go ahead. That was the big red warning light for me! I knew then that his priorities were backwards and all about shrooms.
For what it’s worth one should not forget that this is a ultra high risk penny stock. Like soooo many others on the otc, the vast, vast majority in this category fail or R/S which wipes out the SH. I personally have war wounds. IMO only $ one can afford to lose should be invested here. Ihub used to have a ‘OTC Graveyard’ board. It was huge. They finally removed it due to it negative connotations. JMHO.
Yes, and that was our hope with RLFTF too. But the big pharma buyout never happened. It's just a pipe dream IMO. But then again, stranger things have happened. There are investors on RLFTF that lost hundreds of thousands of dollars. And I'm sure that there are some here are sitting on those type of losses too. However, the insiders always win, and Michael Frank still gets his big fat salaries and bonuses. It is what it is.
Our sibling foreign (RVVTF), tiny biotech is getting hammered today. Stagnation with the FDA process. Down to 4 cents now. Lot's of longs got burned over there just like lots of longs got burned here. Incompetence with senior mgmt there, just like here.
And just like RLFTF, the CEO (Michael Frank) and other fat cat insiders still get their fat salaries and bonus checks. No loss for them. They still did just fine in the pandemic.
As predicted, RVVTF followed the same path as RLFTF. Both foreign tiny biotechs, and the FDA doesn't give them the attention they give USA Big Pharma. I saw this coming, and I feel bad for the longs. I've also never had any faith in this CEO's competency level. He's always been too hooked on shrooms. At least the O/S is not in the stratosphere like it is with RLFTF, so I don't think an R/S is on the horizon just yet. But clearly investor patience has worn thin, COVID is winding down, and the big money has already been made for most with this pandemic. JMHO.
None of the news surprises me. It’s the same path I’ve seen other foreign small biotechs who have suffered with the FDA. Real news won’t occur until 2024… (good bad or ugly) The pps will continue to drift south due to inpatient investors. Unfortunately. JMHO.
Acer Therapeutics (NASDAQ:ACER – Get Rating) will be announcing its earnings results on Tuesday, February 28th.
Acer Therapeutics Price Performance
ACER opened at $2.14 on Monday. The company’s 50 day moving average is $2.57 and its 200 day moving average is $1.85. Acer Therapeutics has a 12-month low of $1.11 and a 12-month high of $4.56.
Insider Buying and Selling at Acer Therapeutics
In related news, CEO Chris Schelling purchased 819,672 shares of the company’s stock in a transaction that occurred on Tuesday, November 29th. The stock was bought at an average price of $1.22 per share, for a total transaction of $999,999.84. Following the completion of the transaction, the chief executive officer now owns 2,712,529 shares in the company, valued at approximately $3,309,285.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.20% of the company’s stock.
Institutional Investors Weigh In On Acer Therapeutics
Several large investors have recently added to or reduced their stakes in ACER. Geode Capital Management LLC grew its stake in Acer Therapeutics by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 96,330 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 5,515 shares during the last quarter. Renaissance Technologies LLC raised its position in Acer Therapeutics by 216.8% during the second quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 47,700 shares during the period. Meridian Wealth Management LLC acquired a new position in shares of Acer Therapeutics during the fourth quarter valued at approximately $180,000. Finally, Vanguard Group Inc. boosted its stake in Acer Therapeutics by 55.5% during the 1st quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 99,335 shares during the last quarter. 27.96% of the stock is owned by hedge funds and other institutional investors.
Most, who have done their DD on this, know that it is not.
Many investors here are also grateful that Tim regularly PRs on what is going on with the business. Most pennystocks in this situation have zero communication with SH. Just think about how batty one would feel if there were zero PRs coming out of TSOI (radio silence for years).
My largest concern with this penny stock is the grotesque O/S and float. That makes it prime for a devastating R/S. Tim has promised not to ever do that while on his watch. However, if he hands the control over to a new owner, or he decides to bite the dust, all bets are off on that promise.
An R/S is the single greatest risk to SH IMO. The only way it will work (IMO) is if Tim coordinate the R/S with a move to uplist to the NASDAQ after announcing some major breakthrough with the FDA. Yes, that could happen! But it won't happen tomorrow or this year. If it should happen, it's likely to be several years down the pipe. Until then, funding operations is Tim's biggest challenge. So, this is a longggg term investment IMO. It's also a wild gamble!
No, it is not. Today's PR emphasizes that TSOI is leveraging the "Right to Try Law" which broadens the exposure of this new treatment to other patients 'without' FDA approval. It's a great way to 'get the word out' that a given therapy works. So, this is a positive move in the right direction with this therapy.
Jedi..thanks for keeping us posted that QNTA is still actively promoting, selling and shipping product to customers! That at least demonstrates that the lights are still on.
Well it sure looks like QNTA delivered on this promise (per their PR). Let's hope we see more fulfilled promises down the road.
Thanks for the update. Amazing that this trial is not scheduled for completion until Dec 2023. Which means we won't hear the formal results until we are deep into 2024....long after RAM pulls his R/S stunt.
Why the price collapse today ?
Snoop.. what is not looking good?
yes, I've read about that. However I haven't been able to locate a link to obtain more information on this. Have you?
pegs1, I'm losing hope that any remaining aviptadil trials will make a difference on the RLFTF stock price. So I'm not following the trials as closely as I had in the past. I see treatment for ARDS as the only short term hope for SH. Maybe ACER if they can start generating sales now that ACER 001 has been approved.
This trial was supposed to have completed by Dec 2022, so I would suspect that we'll hear something about those results. https://clinicaltrials.gov/ct2/show/NCT04536350
I'm still waiting for the formal release of the NIH trial results.
I'm not aware of any 'ongoing' aviptadil trial that is seeking new patients. Sorry. Have you tried reaching out directly to RLFTF for any information on ongoing trials?
As part of the FDA's Coronavirus Treatment Acceleration Program, Relief Therapeutics, a Swiss company, is examining the effectiveness of Aviptadil, a patented synthetic version of a human vasoactive intestinal polypeptide (VIP), for COVID-19-related ARDS at New York University Langone (NYU Langone Health) (CTAP).
Do a find on : "Relief"
https://www.bloomberg.com/press-releases/2023-01-31/at-7-5-cagr-global-peptide-synthesis-market-size-share-to-surpass-us-845-68-million-by-2028-peptide-synthesis-industry
Red Tape! Yes, that is often the killer due to the lengthy time required. I have no evidence, but I also don't feel that the FDA is quite as friendly to foreign entities as they are with US entities.
If bucil had so much promise, then why didn't he dilute more to raise the capital to help stay in the EUA race?
I do. JMHO. The question is ... how much. Now if today's PR included specifics on new quantified revenues that are hitting the financial statements - that would be a whole different (bullish) matter.
Very Good!